Cargando…
Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment modalities and additionally novel combinations that...
Autores principales: | Liu, Marisa C, Tewari, Krishnansu S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310180/ https://www.ncbi.nlm.nih.gov/pubmed/30627206 http://dx.doi.org/10.7573/dic.212558 |
Ejemplares similares
-
Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer
por: Eskander, Ramez N., et al.
Publicado: (2014) -
Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies
por: Tewari, Krishnansu S.
Publicado: (2016) -
Synthetic Lethality in Ovarian Cancer
por: Chandrasekaran, Akshaya, et al.
Publicado: (2021) -
Synthetic lethality guiding selection of drug combinations in ovarian cancer
por: Heinzel, Andreas, et al.
Publicado: (2019) -
Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition
por: Shen, John Paul, et al.
Publicado: (2015)